NanoString® Technologies develops innovative products that unlock valuable and clinically actionable genomic information from small amounts of tissue. We are committed to providing tools that enable scientists and clinicians to translate today’s leading research into clinically actionable tests that improve patient care.

The nCounter® Analysis System and related consumables have been adopted by academic, government and commercial research laboratories worldwide. NanoString Technologies (or: “The Company”) obtained CE Mark in September 2012, and FDA 510(k) clearance in September 2013, for the Prosigna™ Breast Cancer Assay representing our initial offering in the molecular diagnostics market.